IRIS Accounts Production v25.2.0.378 13876617 Board of Directors 1.1.24 31.12.24 31.12.24 26.9.25 false true false false true false Auditors Opinion Ordinary 1.00000 Ordinary 0.01000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh138766172023-12-31138766172024-12-31138766172024-01-012024-12-31138766172022-12-31138766172023-01-012023-12-31138766172023-12-3113876617ns15:EnglandWales2024-01-012024-12-3113876617ns14:PoundSterling2024-01-012024-12-3113876617ns10:Director12024-01-012024-12-3113876617ns10:PrivateLimitedCompanyLtd2024-01-012024-12-3113876617ns10:SmallEntities2024-01-012024-12-3113876617ns10:Audited2024-01-012024-12-3113876617ns10:SmallCompaniesRegimeForDirectorsReport2024-01-012024-12-3113876617ns10:SmallCompaniesRegimeForAccounts2024-01-012024-12-3113876617ns10:FullAccounts2024-01-012024-12-3113876617ns10:OrdinaryShareClass12024-01-012024-12-3113876617ns10:OrdinaryShareClass22024-01-012024-12-3113876617ns10:Director22024-01-012024-12-3113876617ns10:Director42024-01-012024-12-3113876617ns10:Director62024-01-012024-12-3113876617ns10:RegisteredOffice2024-01-012024-12-3113876617ns5:CurrentFinancialInstruments2024-12-3113876617ns5:CurrentFinancialInstruments2023-12-3113876617ns5:ShareCapital2024-12-3113876617ns5:ShareCapital2023-12-3113876617ns5:SharePremium2024-12-3113876617ns5:SharePremium2023-12-3113876617ns5:RetainedEarningsAccumulatedLosses2024-12-3113876617ns5:LeaseholdImprovements2024-01-012024-12-3113876617ns5:PlantMachinery2024-01-012024-12-3113876617ns5:FurnitureFittings2024-01-012024-12-3113876617ns5:PlantMachinery2023-12-3113876617ns5:PlantMachinery2024-12-3113876617ns5:PlantMachinery2023-12-3113876617ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-3113876617ns5:WithinOneYearns5:CurrentFinancialInstruments2023-12-3113876617ns5:WithinOneYear2024-12-3113876617ns5:WithinOneYear2023-12-3113876617ns5:BetweenOneFiveYears2024-12-3113876617ns5:BetweenOneFiveYears2023-12-3113876617ns5:AllPeriods2024-12-3113876617ns5:AllPeriods2023-12-3113876617ns10:OrdinaryShareClass12024-12-3113876617ns10:OrdinaryShareClass22024-12-31
REGISTERED NUMBER: 13876617 (England and Wales)











Financial Statements

for the Year Ended 31 December 2024

for

Bio Scope Technologies Ltd

Bio Scope Technologies Ltd (Registered number: 13876617)






Contents of the Financial Statements
for the Year Ended 31 December 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


Bio Scope Technologies Ltd

Company Information
for the Year Ended 31 December 2024







DIRECTORS: J A Gomarsall
N J Razey
R K Edwards
R Bolton



REGISTERED OFFICE: Eldo House
Kempson Way
Bury St. Edmunds
Suffolk
IP32 7AR



REGISTERED NUMBER: 13876617 (England and Wales)



SENIOR STATUTORY AUDITOR: James Knights BSc FCA



AUDITORS: Knights Lowe Limited
Eldo House
Kempson Way
Suffolk Business Park
Bury St Edmunds
Suffolk
IP32 7AR

Bio Scope Technologies Ltd (Registered number: 13876617)

Balance Sheet
31 December 2024

2024 2023
as restated
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 1,763,480 1,277,837

CURRENT ASSETS
Stocks 862,100 248,230
Debtors 5 277,046 167,480
Cash at bank 76,440 19,073
1,215,586 434,783
CREDITORS
Amounts falling due within one year 6 6,879,623 4,441,872
NET CURRENT LIABILITIES (5,664,037 ) (4,007,089 )
TOTAL ASSETS LESS CURRENT LIABILITIES (3,900,557 ) (2,729,252 )

CAPITAL AND RESERVES
Called up share capital 8 150 100
Share premium 989,951 -
Retained earnings (4,890,658 ) (2,729,352 )
SHAREHOLDERS' FUNDS (3,900,557 ) (2,729,252 )

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 26 September 2025 and were signed on its behalf by:





R Bolton - Director


Bio Scope Technologies Ltd (Registered number: 13876617)

Notes to the Financial Statements
for the Year Ended 31 December 2024

1. STATUTORY INFORMATION

Bio Scope Technologies Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going Concern
Having reviewed the projected results and cash flow forecasts of the company the directors are confident that the company will be able to meet its cash obligations in the foreseeable future.

The company is in an intensive phase of research and development that brings a requirement for funds in addition to that needed for day to day trading. This funding has been provided in the year by the directors, shareholders and the parent company via both capital and loan funding. The company has the continued support of these stakeholders, who are committed to supporting the company as necessary through this phase.

The directors are therefore confident that the cash demands of the company will be satisfied, and it is therefore appropriate to prepare the financial statements on the going concern basis.

Related party exemption
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Turnover represents the sales value of work completed at the balance sheet date excluding VAT. The Company's contractual obligations are performed over time therefore revenue is recognised as the contract activity progresses to reflect the Company's partial performance of its contractual obligations. Revenue is calculated by reference to the value of work performed.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Leasehold property - 10% straight line
Plant and machinery - 25% on reducing balance
Equipment - 15% on reducing balance

Bio Scope Technologies Ltd (Registered number: 13876617)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

2. ACCOUNTING POLICIES - continued

Stocks
There are different types of stock that the company hold which are valued as follows:

Recycling material
This is weighed at year-end and valued at cost per kilogram.

Work In Progress
Recycling material that is part way through the refining process is weighed at the year end, and a cost applied based on the original cost of the recycling material being processed. This cost does not include the cost of the processing or any overhead absorption.

Finished Goods
Any finished goods that consists of fully processed material is weighed at year-end and a conservative scrap material price is used based on the current London Metal Exchange prices.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development
Expenditure on research and development is written off in the year in which it is incurred.


Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Bio Scope Technologies Ltd (Registered number: 13876617)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

2. ACCOUNTING POLICIES - continued

Impairment
At each reporting date, goodwill and other fixed assets, including tangible fixed assets and investments but excluding investment properties, are assessed to determine whether there is an indication that the carrying amount of an asset may be more than its recoverable amount and that the asset should be impaired. If there is an indication of possible impairment, the recoverable amount of an asset, which is the higher of its value in use and its net realisable value, is estimated and compared with its carrying amount. If the recoverable amount is lower, the carrying amount of the asset is written down to its estimated recoverable amount and an impairment loss is recognised in profit and loss.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 18 (2023 - 17 ) .

4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 January 2024 1,651,042
Additions 844,318
At 31 December 2024 2,495,360
DEPRECIATION
At 1 January 2024 373,205
Charge for year 358,675
At 31 December 2024 731,880
NET BOOK VALUE
At 31 December 2024 1,763,480
At 31 December 2023 1,277,837

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
as restated
£    £   
Trade debtors 1,081 -
Other debtors 275,965 167,480
277,046 167,480

Bio Scope Technologies Ltd (Registered number: 13876617)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
as restated
£    £   
Trade creditors 148,885 36,264
Amounts owed to group undertakings 6,368,965 4,044,787
Taxation and social security 34,083 17,832
Other creditors 327,690 342,989
6,879,623 4,441,872

7. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:
2024 2023
as restated
£    £   
Within one year 125,000 125,000
Between one and five years 177,083 302,083
302,083 427,083

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: as restated
£    £   
100 Ordinary £1 - 100
14,950 Ordinary £0.01 150 -
150 100

On 8 May 2024 the existing class of 100 Ordinary Shares of £1 each were subdivided into 10,000 Ordinary Shares of £0.01 each .

On 8 May 2024 4,950 Ordinary Shares of £0.01 each were issued for consideration of £200 per share which amounts to £990,000.

On 18 February 2025 7,000 Ordinary Shares of £0.01 each were issued for consideration of £200 per share which amounts to £1,400,000.

9. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

James Knights BSc FCA (Senior Statutory Auditor)
for and on behalf of Knights Lowe Limited

Bio Scope Technologies Ltd (Registered number: 13876617)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

10. PENSION COMMITMENTS

The Company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Company in an independently administered fund. The pension cost charge represents contributions payable by the Company to the fund and amounted to £28,936 (2023 £34,454). Contributions totalling £4,789 (2023 £Nil) were payable to the fund at the balance sheet date and included in creditors.

11. CAPITAL COMMITMENTS
2024 2023
as restated
£    £   
Contracted but not provided for in the
financial statements - 178,604

12. RELATED PARTY DISCLOSURES

During the year, a debt for equity swap took place where debt in Bio Scop 3 Ltd was converted to equity in Bio Scope Technologies Ltd. See note 10 for details.

13. ULTIMATE CONTROLLING PARTY

The immediate and ultimate parent undertaking is Bio Scope 3 Ltd.

There are no individual controlling parties.

14. SHARE-BASED PAYMENT TRANSACTIONS

The company operates an Unapproved Share Scheme under which share options were granted to employees to incentivise and retain key staff.

Options vest upon an exit event. They lapse if the employee resigns or are dismissed.

The fair value of the options granted has been measured at the grant date and will be accounted for in accordance with Section 26 of FRS 102 - Share-based Payment. The share-based payment expense will be recognised in the profit and loss account over the vesting period.

As there is currently no reliable basis to determine a probable valuation or timing of a vesting date, no expense has been recognised in the current year. The total recognised expense for the current year is £nil.